Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119838) titled 'Transformation to the TCbHPy regimen for early or locally advanced HR-/HER2+ breast cancer patients insensitive to 2 cycles of TCbHP neoadjuvant therapy:A prospective, exploratory, phase II, multicenter study' on March 4.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Condition:
Early or locally advanced HR-/HER2+ breast cancer
Intervention:
The insensitive group (tumor regression rate <40% after two cycles):Switch to the TCbHPy treatment regimen and continue until the end of s...